Viking Therapeutics Schedules Q1 2026 Earnings Call Amid Key Clinical Trials
Event summary
- Viking Therapeutics will release Q1 2026 financial results on April 29, 2026, after market close.
- Conference call scheduled for 4:30 p.m. Eastern Time on April 29, 2026.
- Company is advancing Phase 3 trials for VK2735 in obesity (VANQUISH-1 and VANQUISH-2).
- VK2809 achieved primary and secondary endpoints in Phase 2b NASH trial.
- VK0214 showed significant reductions in VLCFAs in Phase 1b X-ALD trial.
The big picture
Viking Therapeutics is navigating a critical phase in its clinical pipeline, with multiple compounds showing promise in metabolic and endocrine disorders. The upcoming earnings call comes as the company advances high-stakes trials in obesity and NASH, areas with significant market potential. Investors will be watching for signs of sustained momentum in both clinical and financial performance.
What we're watching
- Clinical Progress
- The pace at which VK2735 advances through Phase 3 trials will determine its competitive positioning in the obesity market.
- Regulatory Pathways
- Whether VK2809's positive Phase 2b results translate into accelerated regulatory approval for NASH treatment.
- Financial Performance
- How Viking Therapeutics balances clinical development costs with financial sustainability in Q1 2026.
Related topics